573 FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies

• Edmund Poon,
• Michelle Morrow,
• Wenjia Liao,
• Neil Brewis,
• Matthew Lakins,
• Emma McConnell,
• Quincy Kaka,
• Jennifer Ofoedu,
• Cristian Gradinaru,
• Raffaella Giambalvo,
• Miguel Gaspar

Affiliations

Edmund Poon

Aff3 grid.417815.e0000000104335842MedImmune Cambridge United Kingdom

Michelle Morrow

F-Star Biotechnology Ltd, Cambrige, UK

Wenjia Liao

F-Star Biotechnology Ltd, Cambrige, UK

Neil Brewis

F-Star Biotechnology Ltd, Cambrige, UK

Matthew Lakins

F-star Therapeutics Inc, Cambridge, UK

Emma McConnell

F-star Therapeutics Inc, Cambridge, UK

Quincy Kaka

F-star Therapeutics Inc, Cambridge, UK

Jennifer Ofoedu

F-star Therapeutics Inc, Cambridge, UK

Cristian Gradinaru

F-star Therapeutics Inc, Cambridge, UK

Raffaella Giambalvo

F-star Therapeutics Inc, Cambridge, UK

Miguel Gaspar

F-star Therapeutics Inc, Cambridge, UK